Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 11319
TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606867BDBM606867(US11685738, Compound A3)
Affinity DataIC50: 0.570nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606865BDBM606865(US11685738, Compound A4)
Affinity DataIC50: 1.40nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606917BDBM606917(US11685738, Compound A23)
Affinity DataIC50: 4.30nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606955BDBM606955(US11685738, Compound A21-2)
Affinity DataIC50: 4.60nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606865BDBM606865(US11685738, Compound A4)
Affinity DataIC50: 5.69nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606947BDBM606947(US11685738, Compound A15s)
Affinity DataIC50: 5.92nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606954BDBM606954(US11685738, Compound A21 | acid )
Affinity DataIC50: 7.64nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606883BDBM606883(US11685738, Compound A6)
Affinity DataIC50: 8.25nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606864BDBM606864(US11685738, Compound A1)
Affinity DataIC50: 8.30nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606866BDBM606866(US11685738, Compound A2)
Affinity DataIC50: 9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606947BDBM606947(US11685738, Compound A15s)
Affinity DataIC50: 9.28nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 50134778BDBM50134778((S)-3-(6-Methoxy-pyridin-3-yl)-3-{2-oxo-3-[3-(5,6,...)
Affinity DataIC50: 9.57nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606881BDBM606881(US11685738, Compound A5)
Affinity DataIC50: 9.97nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606884BDBM606884(US11685738, Compound A7)
Affinity DataIC50: 11.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606866BDBM606866(US11685738, Compound A2)
Affinity DataIC50: 11.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606864BDBM606864(US11685738, Compound A1)
Affinity DataIC50: 13.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606917BDBM606917(US11685738, Compound A23)
Affinity DataIC50: 14.8nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606919BDBM606919(US11685738, Compound A28 | acid )
Affinity DataIC50: 16.9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606918BDBM606918(US11685738, Compound A24 | acid )
Affinity DataIC50: 17.5nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 50134778BDBM50134778((S)-3-(6-Methoxy-pyridin-3-yl)-3-{2-oxo-3-[3-(5,6,...)
Affinity DataIC50: 17.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606867BDBM606867(US11685738, Compound A3)
Affinity DataIC50: 18.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606865BDBM606865(US11685738, Compound A4)
Affinity DataIC50: 21.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606883BDBM606883(US11685738, Compound A6)
Affinity DataIC50: 24nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606919BDBM606919(US11685738, Compound A28 | acid )
Affinity DataIC50: 34.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606918BDBM606918(US11685738, Compound A24 | acid )
Affinity DataIC50: 35.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606955BDBM606955(US11685738, Compound A21-2)
Affinity DataIC50: 50.3nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606881BDBM606881(US11685738, Compound A5)
Affinity DataIC50: 63.9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606881BDBM606881(US11685738, Compound A5)
Affinity DataIC50: 65.7nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606866BDBM606866(US11685738, Compound A2)
Affinity DataIC50: 78.1nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606867BDBM606867(US11685738, Compound A3)
Affinity DataIC50: 79.3nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606884BDBM606884(US11685738, Compound A7)
Affinity DataIC50: 80.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606954BDBM606954(US11685738, Compound A21 | acid )
Affinity DataIC50: 88.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606917BDBM606917(US11685738, Compound A23)
Affinity DataIC50: 151nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 606883BDBM606883(US11685738, Compound A6)
Affinity DataIC50: 190nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent